Shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) traded up 0% during mid-day trading on Friday . The stock traded as high as $18.45 and last traded at $18.30. 2,270,479 shares changed hands during mid-day trading, an increase of 51% from the average session volume of 1,507,231 shares. The stock had previously closed at $18.30.

Several analysts recently issued reports on the stock. Jefferies Group reaffirmed a “buy” rating and issued a $18.00 price target on shares of Sangamo Therapeutics in a report on Friday, October 13th. Piper Jaffray Companies raised shares of Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price target on the stock in a report on Wednesday, November 15th. BidaskClub raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, December 29th. Zacks Investment Research raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Wednesday, November 15th. Finally, Barclays assumed coverage on shares of Sangamo Therapeutics in a report on Wednesday, November 22nd. They issued an “overweight” rating and a $20.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $18.83.

The company has a current ratio of 5.64, a quick ratio of 5.64 and a debt-to-equity ratio of 0.02. The company has a market cap of $1,550.00, a P/E ratio of -26.52 and a beta of 3.15.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The firm had revenue of $11.81 million during the quarter, compared to analyst estimates of $10.37 million. During the same quarter in the previous year, the firm earned ($0.27) earnings per share. The firm’s revenue for the quarter was up 333.0% compared to the same quarter last year. equities analysts anticipate that Sangamo Therapeutics Inc will post -0.73 earnings per share for the current year.

In other Sangamo Therapeutics news, VP Edward R. Conner sold 5,000 shares of the business’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $17.11, for a total transaction of $85,550.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Curt A. Herberts III sold 11,803 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $18.00, for a total transaction of $212,454.00. Following the sale, the vice president now owns 27,636 shares of the company’s stock, valued at approximately $497,448. The disclosure for this sale can be found here. In the last quarter, insiders have sold 58,433 shares of company stock valued at $979,696. 5.50% of the stock is owned by insiders.

Several institutional investors have recently added to or reduced their stakes in SGMO. Russell Investments Group Ltd. bought a new position in shares of Sangamo Therapeutics during the second quarter worth about $203,000. Schwab Charles Investment Management Inc. grew its position in shares of Sangamo Therapeutics by 0.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 267,293 shares of the biopharmaceutical company’s stock worth $2,353,000 after acquiring an additional 1,558 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Sangamo Therapeutics by 2.0% during the second quarter. Bank of New York Mellon Corp now owns 339,842 shares of the biopharmaceutical company’s stock worth $2,990,000 after acquiring an additional 6,537 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of Sangamo Therapeutics by 6.8% during the second quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 832 shares during the last quarter. Finally, Swiss National Bank grew its position in shares of Sangamo Therapeutics by 26.4% during the second quarter. Swiss National Bank now owns 143,560 shares of the biopharmaceutical company’s stock worth $1,263,000 after acquiring an additional 30,000 shares during the last quarter. Institutional investors and hedge funds own 64.33% of the company’s stock.

WARNING: This report was originally posted by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.watchlistnews.com/sangamo-therapeutics-sgmo-trading-0-higher/1806916.html.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.